Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CTI BIOPHARMA CORPCTIC · Entity 111865 | Director | October 02, 2016 | October 03, 2016 |
| TuHURA Biosciences, Inc./NVHURA · Entity 6601 | Director · Chief Executive Officer | May 28, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CTI BIOPHARMA CORP
Report date October 02, 2016 · Filed October 03, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2018-10-14 | Direct | 2,000,000 |
Reported balance
After 2016-10-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-10-02 · Grant · Acquired 2,000,000 · Balance 2,000,000 |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.37 · Expires 2018-10-14 | Direct | 4,539,290 |
Reported balance
After 2016-10-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-10-02 · Grant · Acquired 4,539,290 · Balance 4,539,290 |
TuHURA Biosciences, Inc./NV
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,173,307 |
Reported balance
After 2026-05-28 transaction · row 1
1 source rowRow 1 · 2026-05-28 · Gift · Disposed 150,000 · Balance 2,173,307 F1: Represents gifts to adult sons who do not share same household with reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents gifts to adult sons who do not share same household with reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2026 Filed May 29, 2026 20:37 UTC | TuHURA Biosciences, Inc./NV HURA · Entity 6601 | GiftCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000897069-26-001285 · form4.xml · nonDerivative · entry 1 Bianco James A. · CIK 0001198554 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,173,307 F1 · kind: Represents gifts to adult sons who do not share same household with reporting person. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:33 UTC | TuHURA Biosciences, Inc./NV HURA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 610,332 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0000897069-26-000111 · form4.xml · derivative · entry 1 Bianco James A. · CIK 0001198554 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 610,332 Underlying: Common Stock · 610,332 shares Expires 2036-01-06 F1 · derivative.exercise_date: Represents a supplemental option grant to the option grant previously made in December 2025. One-third of the stock options become exercisable on the first, second, and third anniversary of January 6, 2025. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 11:36 UTC | TuHURA Biosciences, Inc./NV HURA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 3,414,891 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0000897069-25-001807 · form4.xml · derivative · entry 1 Bianco James A. · CIK 0001198554 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,414,891 Underlying: Common Stock · 3,414,891 shares Expires 2035-12-12 F1 · derivative.exercise_date: One-third of the stock options become exercisable on the first, second, and third anniversary of December 12, 2025. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 21:48 UTC | TuHURA Biosciences, Inc./NV HURA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 1,065,990 | $0.00 Strike: $4.94 | $0.00 |
DisclosureSEC source: 0000897069-24-002166 · form4.xml · derivative · entry 1 Bianco James A. · CIK 0001198554 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,065,990 Underlying: Common Stock · 1,065,990 shares Expires 2034-11-12 F1 · derivative.exercise_date: One-third of the stock options become exercisable on the first, second, and third anniversary of November 12, 2024. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 00:10 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 191,280 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0000897069-24-001996 · form4.xml · derivative · entry 4 Bianco James A. · CIK 0001198554 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,280 Underlying: Common Stock · 191,280 shares Expires 2034-02-28 F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc." F3 · derivative.exercise_date: One-third of the stock options become exercisable on the first, second and third anniversary of February 28, 2024. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 00:10 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 71,560 | $0.00 Strike: $3.69 | $0.00 |
DisclosureSEC source: 0000897069-24-001996 · form4.xml · derivative · entry 3 Bianco James A. · CIK 0001198554 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,560 Underlying: Common Stock · 71,560 shares Expires 2033-04-07 F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc." F2 · derivative.exercise_date: One-third of the stock options become exercisable on the first, second, and third anniversary of April 7, 2023. Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 00:10 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 357,800 | $0.00 Strike: $3.69 | $0.00 |
DisclosureSEC source: 0000897069-24-001996 · form4.xml · derivative · entry 2 Bianco James A. · CIK 0001198554 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 357,800 Underlying: Common Stock · 357,800 shares Expires 2031-07-01 F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc." Read SEC document |
| October 18, 2024 Filed Oct 23, 2024 00:10 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantCommon Stock | 2,323,307 | $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001996 · form4.xml · nonDerivative · entry 1 Bianco James A. · CIK 0001198554 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,323,307 F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc." Read SEC document |
| October 02, 2016 Filed Oct 3, 2016 20:39 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | GrantEmployee Stock Option (Right to Buy) · Derivative | 4,539,290 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0000899243-16-030608 · doc4.xml · derivative · entry 2 BIANCO JAMES A · CIK 0001198554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,539,290 Underlying: Common Stock · 4,539,290 shares Expires 2018-10-14 Read SEC document |
| October 02, 2016 Filed Oct 3, 2016 20:39 UTC | CTI BIOPHARMA CORP CTIC · Entity 111865 | GrantEmployee Stock Option (Right to Buy) · Derivative | 2,000,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0000899243-16-030608 · doc4.xml · derivative · entry 1 BIANCO JAMES A · CIK 0001198554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2018-10-14 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.